Developer docs
API playgroundTry for free, no card

Search company profiles

Zymetech

Full company profile

uuid000klic

Namestring
Zymetech
Websiteurl
zymetech.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Zymetech is a private Icelandic biotechnology company headquartered in Reykjavík, founded in 1999. The company specializes in the research, development, production, and sales of marine-derived enzymes for therapeutic applications, positioning itself as a globally focused player in a niche segment of enzyme-based therapeutics derived from marine biological sources.

The firm operates with 11-50 employees according to available firmographic data, indicating a small to mid-sized specialty biotech. Zymetech has historically secured non-dilutive or grant-style funding from Iceland's Technology Development Fund, with five disclosed rounds between 2009 and 2015 totaling approximately $873,887. This funding pattern is consistent with a research-intensive, pre-commercial or early-commercial stage company reliant on public innovation financing rather than venture capital.

A significant data integrity caveat applies to this analysis: the aggregated source material contains extensive operational detail about Enzymatica AB, a separately incorporated Swedish company (Lund-based, First North Growth Market-listed under ticker ENZY) that develops a barrier technology cold-prevention spray called ColdZyme. These Enzymatica-specific facts — including its product portfolio, STADA distribution partnership, University of Kent research collaborations, and public market listing — do not pertain to Zymetech and have been excluded from Zymetech's profile. No Zymetech-specific revenue, customer, pricing, or go-to-market data is available in the provided sources.

Short descriptiontext

Zymetech is a private Icelandic biotech company founded in 1999, specializing in research, development, production, and sales of marine-derived enzymes for therapeutic applications, headquartered in Reykjavík with 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
marine-derived enzymes, therapeutic enzymes, marine biotechnology, enzyme production, biotech manufacturing
Industry2 codes
PRIMARYAFAJAIAB
Dairy & Cheese Processing Enzymes
Agriculture & Food Production/Food Ingredients & Additives/Enzymes & Processing Aids (Food Enzymes, Clarifying/Filtering Aids)
SECONDARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Therapeutic enzymes
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zymetech is a globally leading company engaged in the research, development, production, and sales of marine-derived enzymes for therapeutic application. Founded in 1999 in Reykjavík, Iceland, the firm produces enzymes sourced from marine organisms that are used as therapeutic inputs. The company operates as a small specialized manufacturer (11-50 employees) and has historically been funded in part through Icelandic Technology Development Fund grants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • ColdZyme reduces cold duration and symptoms - validated by independent study in Journal of Physiology
+1 more record
Product overview1 text field

Enzymatica offers a platform-based product portfolio centered on its barrier technology platform and the core ColdZyme mouth spray product. The barrier technology platform enables the development of enzymatic formulations that create protective barriers against viruses and microorganisms. ColdZyme is the primary consumer-facing product utilizing this technology, delivered as a mouth spray for cold prevention and symptom relief.

Product and service1 record
1Marine-derived therapeutic enzymes
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-08
Description

Sports sponsorship partnership for Giro d'Italia cycling race to increase brand visibility and marketing reach for ColdZyme products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

International distribution partnership with STADA for ColdZyme products. STADA is a major pharmaceutical company that distributes Enzymatica's products in international markets outside the Nordic region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner in independent clinical studies on ColdZyme effectiveness. Collaborated on peer-reviewed research published in Journal of Physiology.

4Ignaz Semmelweis-institutet and Vetmeduni Wien
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partners in independent studies on ColdZyme. Joint research published in Journal of Physiology confirming the product reduces cold duration and symptoms.

enzymatica.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Swedish enzyme-based therapeutics company (ColdZyme mouth spray) that, like Zymetech, develops enzyme-based products targeting human health. Both operate at the intersection of proprietary enzyme platforms and consumer/therapeutic health applications, though Enzymatica is publicly listed.

TypeDirect peer
Description

Austrian biopharmaceutical company specializing in marine-derived therapeutics (e.g., iota-carrageenan-based products). Most directly comparable peer: builds therapeutic products from marine-sourced compounds, mirroring Zymetech's marine-therapeutic positioning.

TypeRegional player
Description

Icelandic marine ingredients company producing fish oils and marine-derived health ingredients. Comparable via shared Icelandic origin and marine bioresource sourcing, though LYSI focuses on oils rather than therapeutic enzymes.

TypeBroad incumbent
Description

Norwegian marine biotech company harvesting krill and other marine resources for health and nutrition markets. Comparable via marine-sourced bioactive compounds and therapeutic/nutraceutical applications, though at much greater scale.

TypeBroad incumbent
Description

Global enzyme powerhouse with extensive therapeutic and industrial enzyme portfolio. Comparable as the dominant commercial enzyme player; Zymetech competes in a niche within this broader market.

TypeBroad incumbent
Description

Specialty enzyme manufacturer serving food, feed, and industrial applications. Comparable as a specialty enzyme producer, though AB Enzymes is broader in scope and much larger than Zymetech.

TypeEmerging player
Description

UK-based specialist enzyme developer producing bespoke enzymes for food, pharma, and industrial customers. Comparable as a smaller specialty enzyme company developing niche enzyme products, similar in scale and positioning to Zymetech.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zymetech

Therapeutic enzymeszymetech.com

Zymetech is a private Icelandic biotech company founded in 1999, specializing in research, development, production, and sales of marine-derived enzymes for therapeutic applications, headquartered in Reykjavík with 11-50 employees.

What Zymetech does

Zymetech is a private Icelandic biotechnology company headquartered in Reykjavík, founded in 1999. The company specializes in the research, development, production, and sales of marine-derived enzymes for therapeutic applications, positioning itself as a globally focused player in a niche segment of enzyme-based therapeutics derived from marine biological sources.

The firm operates with 11-50 employees according to available firmographic data, indicating a small to mid-sized specialty biotech. Zymetech has historically secured non-dilutive or grant-style funding from Iceland's Technology Development Fund, with five disclosed rounds between 2009 and 2015 totaling approximately $873,887. This funding pattern is consistent with a research-intensive, pre-commercial or early-commercial stage company reliant on public innovation financing rather than venture capital.

A significant data integrity caveat applies to this analysis: the aggregated source material contains extensive operational detail about Enzymatica AB, a separately incorporated Swedish company (Lund-based, First North Growth Market-listed under ticker ENZY) that develops a barrier technology cold-prevention spray called ColdZyme. These Enzymatica-specific facts — including its product portfolio, STADA distribution partnership, University of Kent research collaborations, and public market listing — do not pertain to Zymetech and have been excluded from Zymetech's profile. No Zymetech-specific revenue, customer, pricing, or go-to-market data is available in the provided sources.

Zymetech firmographics

Firmographics
Name
Zymetech
Website
https://zymetech.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Zymetech is a private Icelandic biotech company founded in 1999, specializing in research, development, production, and sales of marine-derived enzymes for therapeutic applications, headquartered in Reykjavík with 11-50 employees.
Ownership category
akta.pro rank

Zymetech industry classification

Industry
Product category
Therapeutic enzymes
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYAFAJAIAB
Dairy & Cheese Processing Enzymes
Agriculture & Food Production/Food Ingredients & Additives/Enzymes & Processing Aids (Food Enzymes, Clarifying/Filtering Aids)
SECONDARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)

Keywords

  • Marine-derived enzymes
  • Therapeutic enzymes
  • Marine biotechnology
  • Enzyme production
  • Biotech manufacturing

Where Zymetech is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Offices1 record

Markets served

Zymetech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Zymetech product offering

Product offering

Core offering

Zymetech is a globally leading company engaged in the research, development, production, and sales of marine-derived enzymes for therapeutic application. Founded in 1999 in Reykjavík, Iceland, the firm produces enzymes sourced from marine organisms that are used as therapeutic inputs. The company operates as a small specialized manufacturer (11-50 employees) and has historically been funded in part through Icelandic Technology Development Fund grants.

Product overview

Enzymatica offers a platform-based product portfolio centered on its barrier technology platform and the core ColdZyme mouth spray product. The barrier technology platform enables the development of enzymatic formulations that create protective barriers against viruses and microorganisms. ColdZyme is the primary consumer-facing product utilizing this technology, delivered as a mouth spray for cold prevention and symptom relief.

Differentiator

Problem solved

Functional benefit

Products and services

  • Marine-derived therapeutic enzymes

Quantifiable outcome

  • ColdZyme reduces cold duration and symptoms - validated by independent study in Journal of Physiology
  • +1 more outcomes

Companies that use Zymetech

Customer profile

Segments1 record

Ideal customer profiles1 record

Zymetech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Zymetech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Unibet Rose RocketsminorGTM or Marketing Partner · 8 June 2026Sports sponsorship partnership for Giro d'Italia cycling race to increase brand visibility and marketing reach for ColdZyme products.
  • STADAcoreChannel Partner/ Reseller/ Distributor · 1 January 2026International distribution partnership with STADA for ColdZyme products. STADA is a major pharmaceutical company that distributes Enzymatica's products in international markets outside the Nordic region.
  • University of KentcoreStrategic or Co-development PartnerAcademic research partner in independent clinical studies on ColdZyme effectiveness. Collaborated on peer-reviewed research published in Journal of Physiology.
  • Ignaz Semmelweis-institutet and Vetmeduni WiencoreStrategic or Co-development PartnerResearch partners in independent studies on ColdZyme. Joint research published in Journal of Physiology confirming the product reduces cold duration and symptoms.

Scale indicators2 records

Recent moves4 records

Expansion highlights1 record

Zymetech competitors and assessment

Company assessment

Direct peers

  • Enzymatica AB: Swedish enzyme-based therapeutics company (ColdZyme mouth spray) that, like Zymetech, develops enzyme-based products targeting human health. Both operate at the intersection of proprietary enzyme platforms and consumer/therapeutic health applications, though Enzymatica is publicly listed.
  • Marinomed Biotech AG: Austrian biopharmaceutical company specializing in marine-derived therapeutics (e.g., iota-carrageenan-based products). Most directly comparable peer: builds therapeutic products from marine-sourced compounds, mirroring Zymetech's marine-therapeutic positioning.

Regional players

  • LYSI hf: Icelandic marine ingredients company producing fish oils and marine-derived health ingredients. Comparable via shared Icelandic origin and marine bioresource sourcing, though LYSI focuses on oils rather than therapeutic enzymes.

Broad incumbents

  • Aker BioMarine: Norwegian marine biotech company harvesting krill and other marine resources for health and nutrition markets. Comparable via marine-sourced bioactive compounds and therapeutic/nutraceutical applications, though at much greater scale.
  • Novonesis (formerly Novozymes): Global enzyme powerhouse with extensive therapeutic and industrial enzyme portfolio. Comparable as the dominant commercial enzyme player; Zymetech competes in a niche within this broader market.
  • AB Enzymes: Specialty enzyme manufacturer serving food, feed, and industrial applications. Comparable as a specialty enzyme producer, though AB Enzymes is broader in scope and much larger than Zymetech.

Emerging players

  • Biocatalysts Ltd: UK-based specialist enzyme developer producing bespoke enzymes for food, pharma, and industrial customers. Comparable as a smaller specialty enzyme company developing niche enzyme products, similar in scale and positioning to Zymetech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

Zymetech social profiles

Digital presence

Zymetech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zymetech leadership team

Management profile

Number of profiles

Profiles1 record

Zymetech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zymetech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zymetech

What does Zymetech do?

Zymetech is a globally leading company engaged in the research, development, production, and sales of marine-derived enzymes for therapeutic application. Founded in 1999 in Reykjavík, Iceland, the firm produces enzymes sourced from marine organisms that are used as therapeutic inputs. The company operates as a small specialized manufacturer (11-50 employees) and has historically been funded in part through Icelandic Technology Development Fund grants.

When was Zymetech founded?

Zymetech was founded in 1999. It employs 11 to 50 people.

Where is Zymetech based?

Zymetech is headquartered in Reykjavík, Iceland, in the Europe region.

Who are Zymetech's main competitors?

Direct peers on record are Enzymatica AB and Marinomed Biotech AG. LYSI hf is listed as a regional player. Broad incumbents are Aker BioMarine, Novonesis (formerly Novozymes) and AB Enzymes. Biocatalysts Ltd is listed as an emerging player.

Does Zymetech have an API?

No public API is recorded for Zymetech.

What industry is Zymetech in?

Zymetech's product category is Therapeutic enzymes. Its primary akta.pro industry code is AFAJAIAB, Dairy & Cheese Processing Enzymes, with a secondary code of AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins). Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales